These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 26351135)

  • 21. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
    Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
    Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2.
    Zhao XQ; Dai CL; Ohnuma S; Liang YJ; Deng W; Chen JJ; Zeng MS; Ambudkar SV; Chen ZS; Fu LW
    Eur J Pharm Sci; 2013 Jun; 49(3):441-50. PubMed ID: 23619284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
    Kort A; van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Pharm; 2017 Oct; 14(10):3258-3268. PubMed ID: 28880088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
    Fischer B; Frei C; Moura U; Stahel R; Felley-Bosco E
    Lung Cancer; 2012 Oct; 78(1):23-9. PubMed ID: 22857894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
    Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
    J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
    Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
    Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.
    Zhang F; Throm SL; Murley LL; Miller LA; Steven Zatechka D; Kiplin Guy R; Kennedy R; Stewart CF
    Biochem Pharmacol; 2011 Jul; 82(1):24-34. PubMed ID: 21459080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
    Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
    Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
    Zhang H; Kathawala RJ; Wang YJ; Zhang YK; Patel A; Shukla S; Robey RW; Talele TT; Ashby CR; Ambudkar SV; Bates SE; Fu LW; Chen ZS
    Int J Biochem Cell Biol; 2014 Jun; 51():111-9. PubMed ID: 24726739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
    Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
    Galetti M; Petronini PG; Fumarola C; Cretella D; La Monica S; Bonelli M; Cavazzoni A; Saccani F; Caffarra C; Andreoli R; Mutti A; Tiseo M; Ardizzoni A; Alfieri RR
    PLoS One; 2015; 10(11):e0141795. PubMed ID: 26536031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
    Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
    Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP).
    Meyer zu Schwabedissen HE; Grube M; Dreisbach A; Jedlitschky G; Meissner K; Linnemann K; Fusch C; Ritter CA; Völker U; Kroemer HK
    Drug Metab Dispos; 2006 Apr; 34(4):524-33. PubMed ID: 16415123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.
    Peng H; Dong Z; Qi J; Yang Y; Liu Y; Li Z; Xu J; Zhang JT
    PLoS One; 2009 May; 4(5):e5676. PubMed ID: 19479068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.